Hospital Medicine Unplugged

In this episode of Hospital Medicine Unplugged, we take on thrombotic thrombocytopenic purpura (TTP)—a hematologic sprint against time. Recognize fast, exchange plasma early, shut down antibody production, and stay ahead of relapse.
TTP is a life-threatening thrombotic microangiopathy marked by microangiopathic hemolytic anemia, severe thrombocytopenia, and organ ischemia. Two types: immune-mediated (iTTP) from anti-ADAMTS13 autoantibodies, and congenital (cTTP) from inherited ADAMTS13 mutations. When ADAMTS13 activity plummets (<10%), ultra-large von Willebrand factor multimers accumulate, driving microvascular platelet-rich thrombi and organ injury.
Diagnosis is clinical—don’t wait for labs. Suspect TTP in any hospitalized patient with MAHA + thrombocytopenia and no alternative explanation. Classic pentad (anemia, thrombocytopenia, neuro findings, renal dysfunction, fever) is rare. Labs: CBC, peripheral smear (schistocytes ≥1%), LDH ↑, haptoglobin ↓, indirect bilirubin ↑, Coombs –, creatinine, and coag studies (typically normal). Send ADAMTS13, but start treatment immediately if TTP is suspected. Use PLASMIC ≥5 or FRENCH ≥1 scores to justify empiric therapy.
First-line therapy = plasma exchange (TPE) + corticosteroids.• TPE removes pathogenic antibodies and restores ADAMTS13.• Corticosteroids (prednisone 1 mg/kg/day or methylprednisolone 1 g IV ×3 days) suppress antibody production.
Adjuncts that change the game:• Rituximab (375 mg/m² weekly ×4)—depletes CD20+ B cells, reducing relapses and accelerating recovery.• Caplacizumab (11 mg IV before first TPE, then 11 mg SC daily)—an anti-VWF nanobody that speeds platelet normalization, cuts exacerbations, and shortens stay—but watch for mucocutaneous bleeding.• Refractory TTP: escalate with twice-daily TPE, additional immunosuppressants (cyclophosphamide, vincristine, cyclosporine), or investigational agents (bortezomib, NAC).• Congenital TTP: recombinant ADAMTS13 is now preferred over plasma infusion when available.
Supportive care pearls:• Avoid platelet transfusion unless there’s life-threatening bleeding.• Provide VTE prophylaxis once platelets >50 × 10⁹/L.• Manage organ dysfunction aggressively (neurologic, cardiac, renal).• Admit all patients—most need ICU-level monitoring.
Monitoring that matters:Daily platelet count, LDH, creatinine, and neurologic checks until recovery. Continue TPE until platelets >150 × 10⁹/L for 48 hours and LDH normalizes. During remission, follow ADAMTS13 monthly in year one, then every 3–6 months. Preemptive rituximab if ADAMTS13 <20%—it can prevent relapse.
Complications to anticipate:• Neurologic injury (stroke, seizure, coma)• Cardiac ischemia or sudden death• Renal impairment, multiorgan failure• Bleeding (esp. with caplacizumab)• Long-term: neurocognitive decline, cardiovascular disease, CKD
Prognosis is vastly improved—with modern therapy, survival exceeds 90%. Relapse risk ~16% at five years, mitigated by early rituximab and vigilant ADAMTS13 monitoring.
Fast recognition, immediate plasma exchange, and smart immunomodulation save lives. In TTP, every hour counts—treat first, confirm later, and never underestimate the comeback.

In this episode of Hospital Medicine Unplugged, we blitz fungemia—treat early, pull the source, and outpace resistance (looking at you, Candida auris).
We open with the do-firsts: draw blood cultures (multiple sets) before therapy if you can, then start an echinocandin—caspofungin, micafungin, or anidulafungin—for most adults. They’re fungicidal, safe, and activity spans non-albicans. Layer rapid diagnostics (e.g., β-D-glucan, T2Candida where available) but don’t delay therapy.
Source control is non-negotiable: yank central venous catheters, drain abscesses, and audit devices/abdominal sites—delays mean higher mortality.
Initial therapy plays (adult, non-neutropenic):• First-line: echinocandin (class considered interchangeable).• Fluconazole step-down only if stable, no recent azole exposure, and isolate susceptible.• Lipid amphotericin B (≈3–5 mg/kg/d) when echinocandins/azoles can’t be used or for refractory/MDR Candida.• Duration: ≥14 days after first negative culture and symptom resolution—longer for deep foci.
Neutropenia & ICU: success rates mirror non-neutropenic patients; prefer non-polyene agents (echinocandins/azoles) for toxicity reasons. Voriconazole is reasonable if you need mold coverage.
C. auris essentials: start with an echinocandin first-line in adults and kids ≥2 months; azole resistance is common. Consider lipid amphotericin B if persistent fungemia or documented resistance. Step-down to an oral azole only with proven susceptibility. Expect higher recurrence; repeat cultures and re-check susceptibilities if breakthrough happens.
Empiric therapy sanity check (Sepsis Campaign): reserve empiric antifungals for real risk (neutropenia, multiple-site Candida colonization, recent abdominal surgery, persistent fever despite broad antibiotics). Routine empiric use doesn’t improve short-term mortality and inflates costs—be targeted.
Eyes & echo: everyone gets daily/every-other-day follow-up cultures until clearance. Dilated fundus exam within 1 week if following older practice; newer data/AAO suggest exam only with ocular symptoms—individualize. Use echo/abdominal imaging if endocarditis or deep foci suspected.
Step-down & tailoring:• Switch from echinocandin to oral fluconazole (800 mg load → 400 mg/d) once stable, cleared blood, and susceptible species (e.g., C. albicans, parapsilosis, tropicalis).• C. glabrata: consider high-dose fluconazole or voriconazole only with confirmed susceptibility; otherwise stay echinocandin.• C. krusei: voriconazole or echinocandin—no fluconazole.
Supportive care pearls: avoid platelet transfusions unless life-threatening bleeding; start VTE prophylaxis when platelets >50 × 10⁹/L; watch renal/hepatic labs and drug interactions (azole QT/CYPs, amphotericin nephrotoxicity).
Infection control (esp. C. auris): strict contact precautions, single rooms/cohorting, EPA List P disinfectants (chlorine/hydrogen peroxide); dedicated equipment and surveillance cultures during outbreaks. Public health notification early.
When the backbone buckles: persistent fungemia → confirm source control, re-sample, escalate/alter class (lipid AmB), and consult ID. Consider therapeutic drug monitoring for voriconazole.
Monitoring that sticks: trend platelets, creatinine, LFTs, and drug levels when indicated; repeat imaging if symptoms persist; ensure all criteria before stopping: culture clearance, symptom resolution, no deep focus, neutrophil recovery when relevant.
We close with the system moves—a fungemia bundle that: (1) pre-checks risk + cultures + BDG; (2) defaults to echinocandin first-line with weight/renal dosing; (3) auto-removes CVCs and hunts deep foci early; (4) runs daily/alt-day cultures to document clearance; (5) steps down only with susceptibility + stability; (6) flags C. auris for enhanced isolation + environmental disinfection; (7) embeds stewardship to avoid low-yield empiric use; (8) builds a discharge plan for duration, drug monitoring, and follow-up.
Fast recognition, early echinocandin, ruthless source control, and disciplined step-down—that’s how you turn fungemia from fatal to fixable.

In this episode of Hospital Medicine Unplugged, we blitz Febrile Nonhemolytic Transfusion Reactions (FNHTRs)—the common post-transfusion fever that looks scary, wastes resources, but rarely bites. Diagnose fast, exclude the killers, treat supportively, and don’t give unnecessary meds or antibiotics.
We start with the definition & frequency: ≥1°C rise to ≥38°C or chills/rigors within 4 hours of transfusion, no other cause. Despite universal leukoreduction, FNHTRs still occur in ~0.1–0.3% of transfusions—especially with platelets.
Pathophysiology—two lanes:• Cytokine buildup in storage (IL-1, IL-6, TNF-α), more in platelets > RBCs.• Recipient anti-leukocyte antibodies (anti-HLA/anti-granulocyte) hitting residual donor WBCs.Not hemolysis. Not allergy. Not TRALI. Not sepsis.
Clinical picture: Fever ± chills/rigors during/soon after transfusion, no hemolysis signs (no back pain, hemoglobinuria, jaundice) and no allergic features (urticaria, wheeze). Most cases are mild and self-limited.
Do-firsts at bedside (every time):• Stop the transfusion now. Keep IV with new tubing + NS.• Clerical re-check: patient/product ID.• Call the blood bank; initiate hemovigilance.• Reassess vitals; look for hypotension, dyspnea, back pain, rash.
Must-not-miss differentials (rule out fast):• Acute hemolytic reaction (AHTR): fever + pain, hypotension, +DAT, hemoglobinuria, ↑LDH, ↓haptoglobin.• Septic transfusion reaction: high fever, rigors, hypotension/shock—think platelets; patient + product cultures.• TRALI: acute hypoxemia, bilateral edema ≤6 h, noncardiogenic.• TACO: volume overload—hypertension, ↑BNP, responds to diuretics.• Others: drug fever, TA-GVHD (days–weeks), etc.
Core labs/workup (send immediately):• Repeat ABO/Rh, crossmatch, antibody screen.• DAT (Coombs), plasma/urine free Hgb, bilirubin, LDH, haptoglobin, CBC.• Blood cultures from patient and residual product to exclude sepsis.• Additional tests/imaging if respiratory symptoms (TRALI/TACO pathways).
Management—keep it simple (when serious causes excluded):• Acetaminophen for comfort; observe until symptoms abate.• No empiric antibiotics unless sepsis suspected.• No routine steroids/antihistamines (use only if true allergic features).• Admission not needed unless unstable or workup suggests alternate diagnosis.
If fever is ≥39°C, rigors, hypotension, or organ dysfunction:• Treat as possible AHTR/sepsis → ICU-level monitoring, fluids, early broad IV antibiotics if sepsis suspected, vasopressors as needed, renal protection for hemolysis.• Escalate hemovigilance; track cultures and product investigation.
Prevention that actually works:• Universal leukoreduction (pre-storage preferred).• Restrictive transfusion strategy (Hb 7–8 g/dL thresholds; transfuse the fewest units necessary).• Flawless ID checks & protocol discipline; staff education; robust reporting.• Routine premedication (acetaminophen/antihistamines) is not supported by evidence—reserve for select histories; don’t replace primary prevention.
Monitoring & reporting:• Check vitals during transfusion and for several hours after; document timing and symptoms precisely.• Report every suspected reaction to the transfusion service with complete clinical and lab data—this fuels safety improvements.
Prognosis: Excellent for FNHTR—self-limited, minimal sequelae, low recurrence with leukoreduction/restrictive use. The danger lies in what FNHTR can mimic: AHTR, sepsis, TRALI—recognize and exclude these rapidly.
Bottom line: Stop the unit, exclude the killers, treat symptoms, and prevent the next one. Keep transfusions necessary, leukoreduced, and protocol-tight.

In this episode of Hospital Medicine Unplugged, we decode Euthyroid Sick Syndrome (ESS)—also known as Non-Thyroidal Illness Syndrome (NTIS)—the deadly lab mirage that looks like hypothyroidism but demands restraint, not replacement.
This syndrome appears in the sickest hospitalized patients—sepsis, trauma, burns, heart failure, renal or hepatic failure—where thyroid tests go haywire without true thyroid disease. The classic lab pattern? Low T3, normal or low T4, normal or low TSH, and often elevated reverse T3 from impaired T4→T3 conversion.
Mechanism check: Inflammation and stress cytokines (IL-1, IL-6, TNF-α) suppress deiodinases, dampen hypothalamic TRH, and alter hormone binding—all designed to slow metabolism and conserve energy during critical illness. Early on, peripheral conversion drops; later, the central axis shuts down. It’s not thyroid failure—it’s metabolic triage.
The twist? The deeper the thyroid suppression, the sicker the patient. ICU data show that low free T3 and high rT3 track with mortality, ventilator dependence, and longer ICU stays. In the elderly or malnourished, “low T3 syndrome” predicts frailty and poor outcomes. ESS is a biomarker of danger—not a call for levothyroxine.
Diagnosis pearls:
True hypothyroidism: TSH >20–25 µU/mL, low free T4, ± thyroid antibodies.
ESS/NTIS: Low T3, high rT3, non-elevated TSH.
Central hypothyroidism: Low or inappropriately normal TSH with low T4, often in pituitary disease.Always factor in dopamine, steroids, amiodarone, and critical illness—they all flatten the thyroid axis.
Treatment trap: The American Thyroid Association and Endocrine Society agree—do not replace thyroid hormone in ESS. Randomized trials of T3 or T4 therapy show no survival benefit and even possible harm, especially in patients with renal failure or cardiac compromise. ESS reflects an adaptive slowdown, not a hormone deficiency. Treating it risks undoing the body’s protective metabolic brake.
Exceptions? Only in proven primary hypothyroidism, central hypothyroidism, or myxedema coma—not just low T3. Rare, controversial studies suggest theoretical benefit in “stunned myocardium” or severe cardiac dysfunction, but evidence is thin and practice remains conservative.
Management mantra:• Focus on treating the underlying illness—sepsis, shock, trauma, malnutrition.• Avoid reflex thyroid hormone therapy unless clear hypothyroidism is confirmed.• Recheck thyroid tests after recovery—ESS usually resolves spontaneously.• If TSH rises briefly during recovery, that’s normal reactivation, not disease.
Prognostic reality: ESS isn’t just a lab quirk—it’s a physiologic distress signal. The lower the T3, the higher the risk. But normalizing numbers won’t normalize outcomes; fixing the illness does.
So, the ESS take-home: Recognize the pattern. Resist the reflex. Respect the physiology.When thyroid labs go low in the ICU, remember—the thyroid isn’t sick. The patient is.

In this episode of Hospital Medicine Unplugged, we tackle ischemic limb—act fast for ALI, plan smart for CLTI, save the patient and the leg.
We open with the two phenotypes:• ALI (acute limb ischemia)—sudden arterial cut-off with the 6 Ps: pain, pallor, pulselessness, poikilothermia, paresthesia, paralysis.• CLTI (chronic limb-threatening ischemia)—rest pain, non-healing ulcers, or gangrene on a PAD backdrop (diabetes, renal disease, smoking, age).
Rapid bedside triage—decide viability, not vocabulary: inspect color/temp/mottling; check sensory & motor; palpate pulses; handheld Doppler (arterial/venous signals). Stage it (Rutherford for ALI; Rutherford/WIfI for CLTI) to set urgency.
Imaging that doesn’t slow you down: CTA or duplex to map anatomy only if the limb is viable or marginally threatened; unstable or immediately threatened limbs go straight to revascularization.
ALI do-firsts—time is muscle & nerve:• Heparin now (bolus 5,000–10,000 U, then aPTT-titrated infusion) unless contraindicated.• STAT vascular consult; analgesia, resuscitation, labs (CK, lactate, K⁺ for reperfusion risk).• Revascularize based on stage/etiology: catheter-directed thrombolysis for fresh thrombus or graft/stent occlusion; open embolectomy/bypass for immediately threatened (IIb) limbs, older thrombus, or when speed matters.• Avoid revascularization in Rutherford III (non-viable)—go to primary amputation and optimize physiology.• Post-flow vigilance: monitor for compartment syndrome; low threshold for fasciotomy.
CLTI foundations—treat the patient and the pathway:• Guideline-directed medical therapy for all PAD/CLTI: antiplatelet (aspirin or clopidogrel), high-intensity statin, ACEi/ARB, tight BP/glucose, smoking cessation (behavioral + meds).• Infection & tissue loss: culture-guided antibiotics; sharp debridement; off-loading and advanced wound care.• Revascularization is the rule unless futile:– Surgery (autologous vein bypass): favored in selected anatomy and good conduit—often superior durability in CLTI.– Endovascular (angioplasty/stent/atherectomy): preferred for high-surgical-risk patients or focal/amenable lesions.– Hybrid when needed (e.g., common femoral endarterectomy + endovascular tibials).• After revascularization: consider dual antiplatelet (short course) or dual-pathway inhibition (aspirin + low-dose rivaroxaban) in appropriate patients to reduce MALE/MACE.
When to amputate: non-reconstructable disease, extensive necrosis, overwhelming infection, or prohibitive risk—prioritize a functional level and early rehab planning.
Pearls & pitfalls:• Don’t wait for perfect imaging—reperfuse threatened limbs now.• Neurologic deficits mean the clock is nearly out—escalate to OR.• Completion angiography after open surgery catches fixable issues and reduces reinterventions.• Reperfusion kills, too—anticipate hyperkalemia, acidosis, rhabdo; manage fluids, bicarbonate as needed, and watch compartments.• Toe pressures/TcPO₂ outperform ABI in calcified vessels (diabetes/CKD).
Discharge & durability: statin adherence, antiplatelet/antithrombotic plan, wound follow-up, smoking cessation, foot care, and a clear reintervention pathway. Multidisciplinary CLTI teams (vascular, cardiology, wound, podiatry, rehab, diabetes educators) improve limb salvage and survival.
We close with the hospitalist bundle: (1) Heparin now for ALI → Rutherford stage; (2) Call vascular early; (3) Imaging only if it won’t delay; (4) Choose revascularization by anatomy/urgency/comorbidity (endo vs. bypass vs. hybrid); (5) Post-flow monitor for compartments & electrolytes; (6) GDMT for PAD + smoking cessation; (7) Structured wound and infection plan; (8) Document WIfI and book follow-up.
Fast triage, decisive revascularization, and relentless risk-factor control—that’s how you keep legs (and lives) attached.

In this episode of Hospital Medicine Unplugged, we sprint through necrotizing fasciitis & Fournier’s gangrene—cut early, cut often, cover broadly, resuscitate hard.
We open with the do-firsts: STAT surgical consult and to-OR now when you see rapid progression, systemic toxicity, crepitus/necrosis, or failure to respond to antibiotics. Delays kill—plan repeat debridements q12–36h until only healthy, bleeding tissue remains. Imaging (CT) helps map disease only if stable and must never delay source control.
Empiric antibiotics—start immediately and go big for poly-/monomicrobial disease:• MRSA + strep: vancomycin or linezolid• Broad gram–/anaerobe: piperacillin–tazobactam or a carbapenem or ceftriaxone + metronidazole• If GAS confirmed: penicillin + clindamycin (for toxin shutoff + stationary-phase activity).Tailor to local resistance, de-escalate with OR cultures; consider amikacin in high-MDR settings and antifungal coverage in the profoundly immunocompromised.
Supportive care that saves lives:• Aggressive fluids, early pressors for septic shock, close hemodynamics.• Glycemic control, early nutrition, renal/respiratory support as needed.• Urinary/fecal diversion (suprapubic cath, diverting ostomy) when perineal contamination threatens control.
Surgical strategy—how we win:• Wide, radical debridement beyond skin changes; expect multiple trips (often 3–4).• Re-debride q24–36h (q12–24h if ongoing necrosis) until no necrotic tissue and fascia is viable.• Send deep tissue for culture at index operation.• Plan reconstruction (grafts/flaps) after infection control.
Antibiotic stop line & course:• Continue IV therapy until debridement complete, patient clinically improved, and afebrile 48–72h; then narrow/transition per cultures and site. Duration is individualized—clinical trajectory beats a fixed clock.
Adjuncts—use with judgment:• Negative pressure wound therapy (NPWT) after adequate source control—can speed granulation and simplify closure.• Hyperbaric oxygen/IVIG: not routine; never let them delay OR/ABX/resuscitation.
Risk triage & prognostics:• High-risk: diabetes, immunosuppression, older age, renal/liver disease, alcohol use.• Use FGSI/LRINEC only as adjuncts—clinical shock and tissue death trump the score.
Bedside bundle you can deploy today:• Code Nec Fasc: page surgery/OR, start broad IV ABX, draw cultures, large-bore IVs, fluids/pressors.• Book serial debridements at sign-out.• Order labs q6–12h early (CBC, BMP, lactate), close wound checks.• CT ONLY if stable and uncertainty persists.• Document necrotizing infection for resources and pathway triggers.
Cut first, culture second, cover everything, and keep cutting until it’s clean.

In this episode of Hospital Medicine Unplugged, we tackle hospital malnutrition and refeeding syndrome—screen early, feed smart, monitor relentlessly.
We start with the inpatient playbook: screen every adult at admission (MNA-SF, MUST, NRS-2002), then confirm with GLIM and document the diagnosis. Build an individualized nutrition plan: counseling + the right route—oral first (precision nutrition + fortified ONS), enteral if the gut works, parenteral if it doesn’t. Day-to-day targets: ~20–30 kcal/kg and 0.8–1.5 g/kg protein, adjusted to disease burden and goals. Inflammation may blunt reversibility, so treat the illness while you nourish the patient.
Then we zoom in on refeeding syndrome (RFS)—the metabolic ambush of insulin-driven phosphate, potassium, and magnesium shifts causing hypophosphatemia, edema, arrhythmias, and respiratory failure. Thiamine demand spikes; miss it and you risk Wernicke’s.
Risk-stratify up front (older adults, chronic disease, low BMI, big weight loss, minimal intake, alcohol use, low baseline phosphate/magnesium). For high/very-high risk, start low and go slow:• Calories: ~10–20 kcal/kg/day or <50% of needs, advance over 4–7 days if labs/clinis allow.• Thiamine: 100–300 mg/day IV or PO before and during refeeding.• Electrolytes: aggressively replete phosphate, potassium, magnesium before and during feeding.• Monitoring: daily labs in the first week; watch fluid status, cardiac rhythm, and respiratory function.
If RFS hits: pause or reduce calories/fluids, replete electrolytes + thiamine, and re-advance gradually over 4–7 days. Enteral preferred when feasible; apply the same caution if PN is required.
Where the evidence lands:• Precision nutrition and energy/protein-fortified ONS improve outcomes in large trials.• Most guidelines back cautious initial calories in severe malnutrition/critical illness, though select patients may tolerate a more assertive ramp with tight monitoring and supplementation.• Daily energy/protein targets are a guide—not a cliff—trajectory and tolerance trump speed.
Bedside do-firsts you can deploy today:• Order screening on admission → auto-consult dietetics for positives.• Document malnutrition to unlock resources.• Start thiamine before feeds in at-risk patients; add a standing electrolyte replacement protocol.• Trend phosphate/K/Mg daily x 3–7 days; add telemetry or closer observation for the highest risk.• Prefer enteral, avoid overfeeding, and coordinate with pharmacy for electrolyte/thiamine bundles.• Educate and plan the handoff: discharge nutrition goals, supplements, follow-up labs, and red-flag symptoms.
Pearls & pitfalls:• Don’t chase numbers while ignoring inflammation—treat the driver.• Early steroids aren’t a refeeding fix; the fix is controlled calories + electrolytes + thiamine.• Fluid creep kills—use conservative fluids during the first 72 hours.• Collegial care wins—embed dietitians + pharmacists in the pathway.
We close with a hospitalist RFS bundle: (1) universal screening → GLIM confirmation; (2) thiamine first, then low-start calories with stepwise advance; (3) electrolyte protocol + daily labs; (4) enteral-first strategy; (5) clear hold/reduce criteria (falling phosphate, edema, arrhythmia, rising CO₂); (6) written discharge nutrition plan.
Screen everyone, feed deliberately, and never refeed alone—bring the team.

In this episode of Hospital Medicine Unplugged, we tackle septic arthritis—recognize fast, tap the joint early, drain decisively, hit bugs smartly, and protect the cartilage.
We open with who gets it: elderly, diabetes, immunosuppressed, post-arthroscopy/joint surgery, prostheses, dialysis, active skin infection. Culprits are S. aureus (incl. MRSA), streptococci, and less often Gram-negatives—with MRSA = higher morbidity and mortality.
Call the diagnosis, don’t guess: acute monoarthritis (pain, swelling, warmth, ↓ROM) ± fever. CRP/ESR help but aren’t specific. The rule: aspirate before antibiotics (unless unstable). Send synovial fluid for Gram, culture, WBC + diff; >20,000/µL & >70% PMNs is highly suggestive. Culture in blood culture bottles to boost yield; add molecular assays (e.g., 16S/PCR) if culture-negative. Draw blood cultures. Imaging is adjunctive—US to find/guide effusion, MRI if osteomyelitis/deep infection—but never delay tap/therapy.
Risk-stratify for organisms & cover accordingly:• Default empiric after cultures: anti-staph + strep coverage (e.g., cefazolin or ceftriaxone).• MRSA risk/high prevalence: vancomycin (or alternative per allergy/MIC).• Healthcare exposure, immunocompromise, IVDU, or GU/GI source: add Gram-negative coverage (e.g., ceftriaxone/ceftazidime/pip-tazo based on local data).• Tailor to local antibiogram & Gram stain: GPC clusters → vanc, GNRs → ceftazidime/pip-tazo, GNC → ceftriaxone (think gonococcal).
Source control—the nonnegotiable:• Evacuate pus: repeated aspiration, arthroscopic washout, or open debridement—choose by joint (knee vs hip/shoulder), access, and response.• Large effusions, persistent infection, or failure of aspiration → OR.• Prosthetic joint infection: follow PJI pathways (DAIR vs staged revision); consider biofilm-active regimens when appropriate.
Antibiotic game plan & duration:• Start IV, then early oral step-down once clinically improving, afebrile, organism/susceptibilities known, and CRP trending down—oral is generally not inferior in uncomplicated native joints.• Total 2–4 weeks for uncomplicated native joint after adequate drainage; ~6 weeks if osteomyelitis or complicated course.• Gonococcal: ceftriaxone, short course with rapid response; drain if purulent.
Monitoring that matters:• Daily joint exam & function, pain, ROM.• Trend CRP (best for kinetics) ± ESR/WBC; lack of improvement → re-aspirate and reassess source control.• Watch for HIT, nephrotoxicity, drug interactions; coordinate ID + Ortho/Rheum.
Medication pitfalls you don’t want to meet: delaying aspiration, starting antibiotics before cultures, underdosing MRSA/obesity, skipping Gram-negative coverage in high-risk hosts, forgetting to drain, or over-relying on imaging instead of a needle.
Special plays:• Immunocompromised/IVDU: broaden initial coverage; think Pseudomonas and atypicals; lower threshold for surgical drainage.• Anticoagulated: aspiration is usually safe with precautions; optimize coagulation for OR.• PJI: lower synovial WBC thresholds, longer therapy (6–12 weeks), surgical decision (DAIR vs revision) drives outcomes.
We close with the system bundle: (1) ED/ward “hot joint” pathway that auto-pages aspiration within hours; (2) order set: blood + synovial cultures (in BC bottles), cell count/diff, crystals, Gram ± PCR; (3) empiric antibiotics post-tap with MRSA logic and local antibiogram baked in; (4) drainage escalation checklist; (5) CRP-guided step-down and stop rules; (6) ID/Ortho co-management; (7) PJI branch with DAIR/revision criteria.
Fast aspiration, decisive drainage, culture-directed antibiotics, and relentless reassessment—that’s how you save the joint and the patient.